Blog | Oncotarget

Oncotarget News

EGFR-Targeted Therapy Resistance in Breast and Head & Neck Cancers

July 9, 2025

By synthesizing current insights on both RTK and non-RTK mediated resistance against anti-EGFR therapies, this review aims to guide future research and improve therapeutic strategies for these cancers.”BUFFALO, NY -... read more

Oncotarget

Study Identifies Key Genetic Alterations and Biomarker for Blastic Plasmacytoid Dendritic Cell Neoplasm

July 7, 2025

Our findings demonstrate that the mutational landscape of BPDCN is similar to that observed in other myeloid neoplasms, and we identified CCDC50 as a potential biomarker for this disease.”BUFFALO,... read more

Oncotarget

New Drug Combination Redefines First-Line Treatment for Advanced Urothelial Cancer

July 1, 2025

Recent developments have introduced promising therapies, notably the combination of enfortumab vedotin with pembrolizumab, which is now recommended as the first-line therapy following the EV-302 trial results.”BUFFALO, NY - July... read more

Oncotarget

HER2-Mutated NSCLC in Brazil Shows Diverse Genetic Patterns and Treatment Gaps

June 27, 2025

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented populations, emphasizing the need for comprehensive molecular profiling and expanded access to targeted therapies.”BUFFALO, NY -... read more

Oncotarget

WIN International Molecular Tumor Board Recommends Tailored Treatment for Advanced Colorectal Cancer

June 24, 2025

This case emphasizes the critical role of comprehensive molecular profiling and personalized therapeutic approaches in managing complex mCRC.”BUFFALO, NY - June 24, 2025 – A new precision oncology paper was published... read more